SBScott W. Bagley

Scott W. Bagley

*This is an algorithmically generated author record based on publicly available information.

Scott W. Bagley has a total of 378 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enabling the Synthesis of the 4’‐Thioremdesivir Core

    by Liuqing Wei, Mahesh Kasthuri, Christina Na, Scott Bagley, Aanya Bhalla, James Bradow, Li Chengwei, Zahira Tber, Zhe Chen, Chulho Choi, et al.

    Nucleosides and nucleoside analogs represent a long established and highly important class of pharmaceutical agents, with numerous U.S. Food and Drug Administration (FDA)–approved examples spanning antiviral, anticancer, and immunological indications. Among these, 4′‐thionucleosides—wherein the endocyclic ribose oxygen is replaced by sulfur—have emerged as particularly attractive bioisosteric analogs, frequently exhibiting enhanced pharmacokinetic and pharmacodynamic properties. Despite decades of investigation into 4′‐thionucleosides, the literature overwhelmingly focuses on anomeric N‐linked derivatives, while reports describing C‐linked 4′‐thionucleosides remain remarkably scarce. In this study, we report the first successful synthesis of the parent 4′‐thionucleoside core of remdesivir. In contrast to the well‐established β‐selective deoxycyanation observed in the ribose series, substitution of oxygen with sulfur results in a pronounced reversal of anomeric selectivity, favoring the undesired α‐isomer. This intrinsic bias was overcome through the discovery and exploitation of an unprecedented bridged oxythioketal intermediate, enabling access to the β‐configured product. The relative and absolute stereochemistry was confirmed by single‐crystal x‐ray diffraction, correcting a recent misassignment in the literature. Computational and NMR reaction monitoring studies provide mechanistic insight into thioribose reactivity and establish a framework for controlling anomeric stereochemistry in C‐ linked 4′‐thionucleoside synthesis. These results establish a foundation for future C‐ linked 4′‐thionucleoside antiviral development.

  • Open Access

    Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis

    by Jennifer L. Duffen, Kimberly K. Crouse, Lin Ji, Amy L. Brault, Kristen Ford, Jonathan Brooks, Scott A. Jelinsky, Yizheng Li, Julia H. Shin, Yajuan Zhao, et al.

    Interleukin-2-inducible T cell kinase is expressed by T cells and amplifies T cell receptor-dependent signals. Interleukin-2-inducible T cell kinase deletion or inhibition reduces production of interleukin-4 and interleukin-13, key drivers of atopic dermatitis. Nerve growth factor signals via the receptor tropomyosin-related kinase A and may promote pruritus in atopic dermatitis lesions. Here we describe PF-07245303, a compound which potently inhibits interleukin-2-inducible T cell kinase and tropomyosin-related kinase family kinases capable of inhibiting T cell receptor-mediated cytokine production from CD4 and CD8 T cells and suppressing nerve growth factor-induced human basophil activation. In human skin explants, PF-07245303 demonstrates inhibition of tropomyosin-related kinase A phosphorylation, suppresses cytokine expression from T cell receptor-activated resident T cells and reverses the expression of atopic dermatitis associated genes. Topical application of PF-07245303 reduces proinflammatory and epidermal changes in a dermatitis model using female mice. By inhibiting both pathogenic inflammatory mechanisms, PF-07245303 may have therapeutic value for patients with atopic dermatitis.


  • Annulative Skeletal Diversification of Pyrimidines to Expanded Heteroaromatic Space

    by Philipp Spieß, Atang S. Peloewetse, Antonia Profyllidou, Samantha L. Kraus, Nicolò Santarelli, Takashi Fukuyama, Jeffrey T. Kohrt, Caroline A. Blakemore, Christina G. Na, Richmond Sarpong, et al.

    Single-atom skeletal editing has recently emerged as a powerful strategy for the direct diversification of the heterocyclic cores of various compounds. Yet, methods that enable monocycle-to-bicycle transformations that involve core atom changes remain scarce. Herein, we report a two-step, one-pot protocol that converts pyrimidines into 7-azaindazoles and pyrazolo[1,5-a]pyrimidines, two privileged scaffolds in medicinal chemistry. Fine-tuning the reaction parameters enables chemodivergent control, allowing selective access to either framework, with the pyrimidine scope including pharmaceutical drug molecules. Moreover, the strategy has been extended to afford differently substituted pyrimidines, partially saturated fused skeletons, and quinoline derivatives. Access to this broad, expanded, heteroaromatic space underscores the potential for heterocyclic diversification using this approach.


  • Open Access

    Oxygen migration into carbon–carbon single bonds by photochemical oxidation

    by Cade A. MacAllister, Caitlin R. Lacker, Matthieu F. Maciejewski, Felix Wessels, Desiree M. Bates, Scott W. Bagley, Tehshik P. Yoon

    The editing of organic molecules through single-atom modification is an enabling capability for medicinal chemistry. Although several examples of single-atom insertions into the carbon–carbon double bonds of unsaturated aromatic ring systems have been reported, heteroatom insertions into chemically inert carbon–carbon single bonds are comparatively rare. Here we report a photochemical strategy for the formal migration of oxygen atoms into carbon–carbon single bonds. This protocol is based on the ability of copper(II) salts to induce photochemical homolytic cleavage of carbon–carbon bonds adjacent to alcohols and to mediate oxidative coupling reactions of the resulting organoradical intermediates. Application of this method to cyclic alcohol substrates results in oxygen atom insertions into saturated carbocyclic rings, and its extension to linear alcohol substrates enables atomic permutation of hydroxymethyl functionalities into methyl ethers.


  • Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity

    by Mark E. Schnute, Huixian Wu, John I. Trujillo, Wei Li, David Jonathan Wasilko, Jennifer Alley, Eric P. Arnold, Scott W. Bagley, Gabriel Berstein, David C. Blakemore, et al.

    The G protein-coupled receptor (GPCR) CCR6 mediates the migration of pathogenic immune cells to the site of inflammation in response to the chemokine CCL20. CCR6 is an attractive target for the treatment of chronic autoimmune disease as antagonism of the receptor is expected to block CCL20-mediated immune cell recruitment. High-throughput-screening identified a squaramide-based, allosteric antagonist of CCR6 that potently inhibited CCL20-mediated T cell chemotaxis, but it also inhibited CXCL1-mediated neutrophil chemotaxis through CXCR2 antagonism. Lead optimization achieved differentiation from CXCR2 through identification of a methyl substituent-dependent selectivity switch or “magic methyl for selectivity”. The mechanism for this effect is rooted in different antagonist-induced ligand–receptor behaviors, insurmountable for CCR6 and surmountable for CXCR2. Herein, we report the discovery and preclinical evaluation of the CCR6 antagonist PF-07054894 (18l) which has advanced to clinical trials as a first in class approach targeting the receptor.


  • Peptidylarginine Deiminase (PAD) Inhibitor Optimization through Displacement of a Trapped Water Molecule

    by Mark E. Schnute, Gary M. Chinigo, Kentaro Futatsugi, Masaya Yamaguchi, Scott W. Bagley, Mary Ellen Banker, Jeanne S. Chang, Ming Z. Chen, Won Young Choi, Matthew S. Corbett, et al.

    Excess protein citrullination, a post-translational modification converting arginine to citrulline, has been associated with a range of autoimmune and neurological disorders, as well as cancers. Protein citrullination is mediated by the peptidylarginine deiminase enzyme family (PAD1-4), and inhibition of one or several PAD isozymes in combination may offer a therapeutic approach to targeting these diseases. Building upon the discovery of PAD-PF2, an allosteric inhibitor of PAD1-4, herein, we report on the optimization of potency and pharmacokinetic properties while minimizing hERG channel liabilities within this novel chemical series. Through structure-based ligand design, a structural water was successfully displaced, allowing expansion of the ligand binding site and access to a previously unexplored hydrophobic pocket resulting in a 10-fold improvement in potency. Compound 4f demonstrated potent inhibition of PAD-mediated citrullination in human and rat neutrophils, reduced hERG channel liabilities, and good oral bioavailability in preclinical animal species.


  • Open Access

    Oxygen Migration into Carbon–Carbon Single Bonds by Photochemical Oxidation

    by Cade MacAllister, Caitlin Lacker, Matthieu Maciejewski, Felix Wessels, Desiree Bates, Scott Bagley, Tehshik Yoon

    The editing of organic molecules through single-atom modifications is an enabling capability for medicinal chemistry. While several examples of single-atom insertions into the carbon–carbon double bonds of unsaturated aromatic ring systems have been reported, heteroatom insertions into chemically inert carbon–carbon single bonds are comparatively rare. We report herein a photochemical strategy for formal migration of oxygen atoms into carbon–carbon single bonds. This protocol is based on the ability of copper(II) salts to induce photochemical homolytic cleavage of carbon–carbon bonds adjacent to alcohols and to mediate oxidative coupling reactions of the resulting organoradical intermediates. Application of this method to cyclic alcohol substrates results in oxygen-atom insertions into saturated carbocyclic rings, and its extension to linear alcohol substrates enables atomic permutation of hydroxymethyl functionalities into methyl ethers.

  • Open Access

    A focus on computer vision for non-contact monitoring of catalyst degradation and product formation kinetics

    by Niklaas J. Buurma, Scott W. Bagley

    Chemists know the value of looking at a reaction for clues about reaction progress and success, but what-it-looks-like has never been quantified. Reid and co-workers (C. Yan, M. Cowie, C. Howcutt, K. M. P. Wheelhouse, N. S. Hodnett, M. Kollie, M. Gildea, M. H. Goodfellow and M. Reid, Chem. Sci., 2023, 14, 5323–5331, https://doi.org/10.1039/d2sc05702f) have developed an approach that uses camera footage of reactions to obtain quantitative descriptors of changes in reaction mixtures to support kinetic analysis.


  • Convergent Syntheses of Isomeric Imidazolospiroketones as Templates for Acetyl-CoA Carboxylase (ACC) Inhibitors

    by Chris Limberakis, Aaron C. Smith, Scott W. Bagley, Hatice G. Yayla, Daniel W. Kung, David A. Griffith

    The synthesis of imidazole fused spirocyclic ketones as templates for acetyl-CoA carboxylase (ACC) inhibitors is reported. By completing the spirocyclic ring closure via divergent pathways, the synthesis of these regioisomers from common intermediates was developed. Through an aldehyde homologation/ transmetalation strategy, one isomer was formed selectively. The second desired isomer was obtained via an intramolecular aromatic homolytic substitution reaction. Preparation of these isomeric spiroketones provided templates which, upon elaboration, led to key structure-activity relationship (SAR) points for delivery of potent ACC inhibitors.


  • 6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor

    by Gary E. Aspnes, Scott W. Bagley, Steven B. Coffey, Edward L. Conn, John M. Curto, David J. Edmonds, Julien Genovino, David A. Griffith, Gajendra Ingle, Wenhua Jiao, et al.